Bangor Savings Bank Sells 445 Shares of Illumina, Inc. (NASDAQ:ILMN)

Bangor Savings Bank lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,132 shares of the life sciences company’s stock after selling 445 shares during the quarter. Bangor Savings Bank’s holdings in Illumina were worth $552,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Versant Capital Management Inc raised its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. TD Private Client Wealth LLC raised its stake in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in Illumina during the second quarter worth about $61,000. Finally, Private Trust Co. NA lifted its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several analyst reports. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Leerink Partners boosted their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, November 12th. Finally, Canaccord Genuity Group increased their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $165.95.

Illumina Stock Up 1.9 %

Illumina stock opened at $138.65 on Tuesday. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market capitalization of $21.99 billion, a price-to-earnings ratio of -13.92 and a beta of 1.11. The company’s 50 day simple moving average is $141.76 and its 200 day simple moving average is $131.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period last year, the firm posted $0.33 earnings per share. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.